Four patients presented with acute leukemia of ambiguous or myeloid lineage in association with Langerhans cell histiocytosis and provide evidence suggesting a common origin of the two neoplasms. One patient had a non-constitutional trisomy 21 in both the leukemic blasts and the Langerhans cells indicative of a clonal relationship. A second case expressed CD2, CD13, and CD117 on both the Langerhans cells and the blasts suggesting a possible clonal relationship. All four cases exhibited geographic intermingling of the Langerhans cell histiocytosis and acute leukemia and shared unique features including extramedullary leukemia involving lymph nodes in all cases with Langerhans cell histiocytosis only present in sites involved by acute leukemia. T-cell antigen expression was present in all cases with one meeting criteria for mixed phenotype acute leukemia, T/myeloid, not otherwise specified. These findings support the concept that coexistent Langerhans cell histiocytosis and acute leukemia is clonally related in some cases. Furthermore, these cases of acute myeloid or acute leukemia of ambiguous lineage with Langerhans cell histiocytosis share some unique features suggesting a common underlying neoplastic hematopoietic stem cell.
Four patients presented with acute leukemia of ambiguous or myeloid lineage in association with Langerhans cell histiocytosis and provide evidence suggesting a common origin of the two neoplasms. One patient had a non-constitutional trisomy 21 in both the leukemic blasts and the Langerhans cells indicative of a clonal relationship. A second case expressed CD2, CD13, and CD117 on both the Langerhans cells and the blasts suggesting a possible clonal relationship. All four cases exhibited geographic intermingling of the Langerhans cell histiocytosis and acute leukemia and shared unique features including extramedullary leukemia involving lymph nodes in all cases with Langerhans cell histiocytosis only present in sites involved by acute leukemia. T-cell antigen expression was present in all cases with one meeting criteria for mixed phenotype acute leukemia, T/myeloid, not otherwise specified. These findings support the concept that coexistent Langerhans cell histiocytosis and acute leukemia is clonally related in some cases. Furthermore, these cases of acute myeloid or acute leukemia of ambiguous lineage with Langerhans cell histiocytosis share some unique features suggesting a common underlying neoplastic hematopoietic stem cell. Modern Pathology (2014) 27, 651-656; doi:10.1038/modpathol.2013.181; published online 1 November 2013 Keywords: acute leukemia; acute myeloid leukemia; ambiguous immunophenotype; clonal; Langerhans cell histiocytosis Langerhans cells (LCs) are a type of dendritic cell that characteristically express S100, CD1a, and langerin (CD207) and contain ultrastructural Birbeck granules. LC histiocytosis is a neoplastic proliferation of LCs that can present at a single location or at multiple sites. It is a heterogeneous disease that may have a high mortality when multiple sites are involved or may resolve spontaneously as often occurs with single site disease. 1 Rarely, LC histiocytosis may be associated with various hematologic neoplasms including acute lymphoblastic and myeloid leukemias, other clonal myeloid neoplasms, and lymphomas. [2] [3] [4] Acute lymphoblastic leukemia is more often associated with LC histiocytosis in children, whereas lymphoma and acute myeloid leukemia are more common in adults, which may reflect the frequency of these diseases in the respective populations. 2, 4 Most cases of acute myeloid leukemia associated with LC histiocytosis appear to be treatment related as they occur years after cytotoxic treatment for LC histiocytosis; however, in some cases, LC histiocytosis occurs concurrently or follows acute myeloid leukemia. 2, 4 The biologic relationship of LC histiocytosis with hematologic neoplasms remains to be fully elucidated. In some instances, LC histiocytosis appears to be incidentally associated without evidence of dissemination or progression, 5 whereas in others the LC histiocytosis follows an aggressive course. 6 A clonal relationship between LC histiocytosis and T-lymphoblastic leukemia has been shown in a limited number of cases; 6,7 however, to our knowledge, a clonal relationship has not been demonstrated in LC histiocytosis associated with other acute leukemias. In this report, we describe several cases of acute leukemia of ambiguous or myeloid lineage in association with LC histiocytosis that provide evidence suggesting a common origin between the two neoplasms.
Materials and methods
Four adult patients with acute leukemia and concurrent or subsequent LC histiocytosis were identified over a period of 12 years. Original evaluation of leukemia was performed at different institutions using morphologic examination, flow cytometric immunophenotyping, immunohistochemical stains, and cytogenetic studies. The presence of LCs was confirmed by immunohistochemistry for CD1a, S100, and langerin. FISH was performed on a lymph node of one patient who had a trisomy 21 leukemic clone. As BRAF mutations occur in a significant percentage of LC histiocytosis, 8 BRAF V600E testing was performed in three cases by real-time polymerase chain reaction (RT-PCR). DNA was extracted from formalin-fixed, paraffin-embedded tissue (two cases) or B5-fixed tissue (one case) using the DNeasy blood and tissue kit, and then diluted to a DNA concentration of 66.7 ng/ml. The RT-PCR procedure was modified from Benlloch et al 9 and samples were run on an ABI7900HT (Applied Biosystems, Foster City, CA, USA) with the following controls: 100% tumor, 10% tumor, negative, and no template.
Results
Four patients presented with acute leukemia and concurrent (three cases) or subsequent (one case) LC histiocytosis (see Table 1 ). They were all adults with a median age of 61 (range 36-80) years and three of the four patients were male. All patients either presented with or developed extramedullary leukemia in lymph nodes. Two patients (patients 1 and 4) had concurrent LC histiocytosis and leukemia in both the bone marrow and lymph node, one patient (patient 3) had concurrent LC histiocytosis and leukemia in a lymph node, and one patient (patient 2) presented with isolated leukemia in the bone marrow with subsequent, 4 months later, leukemia and LC histiocytosis in a lymph node. In all four patients, leukemic blasts and LC lesions were geographically intermingled in the involved tissue, and in patients 1 and 3, the leukemic blasts and LCs formed targetoid lesions (see Figures 1-3) . In all patients, LC lesions were not isolated, but only present with leukemia.
The leukemic blasts in all cases expressed at least one T-cell marker and in two patients the leukemic blasts had an ambiguous phenotype (see Table 2 ). Patient 1 had acute myeloid leukemia, not otherwise specified, with the expression of three T-cell One patient (patient 4) had a non-constitutional trisomy 21. FISH analysis of the involved lymph node revealed trisomy 21 in both the LCs and the blasts, supporting a clonal relationship between the two cell types. BRAF V600E analysis was successfully performed in two of the three patients tested (patients 3 and 4) and neither exhibited a mutation.
Discussion
LC proliferations associated with an underlying hematologic neoplasm may be explained by several different mechanisms including: coincidental occurrence of two distinct neoplasms, a reactive proliferation of LCs in association with another neoplasm, development of a myeloid neoplasm secondary to LC histiocytosis therapy, or a clonally related process where the LCs are derived either from a common stem cell or through transdifferentiation of the myeloid neoplasm. There is evidence that different mechanisms may exist in different patients. [5] [6] [7] The biology of cases with a clonal relationship are of particular interest in understanding the lineage connection of these distinct cell types and the possible future impact on treatment of these diseases.
A clonal relationship between LC histiocytosis and T-lymphoblastic leukemia has been established in a small number of cases 6,7 but has not been reported in other acute leukemias. Two of the cases reported here support the concept that concurrent or subsequent LC histiocytosis in patients with underlying hematopoietic neoplasms are, in some cases, clonally related to the underlying neoplasm. In one of the cases (patient 4), a clonal relationship of the leukemia and LC histiocytosis was established by a shared cytogenetic abnormality in the two neoplastic cell lineages by FISH studies on lymph node sections. In another case (patient 2), there is suggestive evidence of a clonal relationship with the expression of CD2, CD13, and CD117 on both the leukemic blasts and the LCs. The presence of myeloid-associated markers is unusual on LCs. 12 The four patients were all adults and shared several infrequent findings that suggest a common underlying biology. Extramedullary leukemia involving lymph nodes was present in all and as a presenting feature in three. There was an intimate geographic relationship of the LC lesions and the leukemia in lymph nodes and/or bone marrow without evidence of LC histiocytosis anatomically separate from the acute leukemia. These unusual findings neither prove nor refute a clonal relationship of the leukemia and LC histiocytosis but suggest commonality among the cases.
The significance of negative BRAF V600E in the two cases is unclear as BRAF V600E can be negative in up to 43% of patients with LC histiocytosis. 8 Young individuals with LC histiocytosis are reportedly more commonly positive for BRAF V600E. 8 The two patients tested in this study were of advanced age (69 and 80 years of age). All of the leukemias in this study were of ambiguous lineage or acute myeloid leukemia that expressed T-cell antigens. It is known that myeloid cells and dendritic cells share a common stem cell and myeloid cells can differentiate into dendritic cells. Furthermore, myeloid neoplasms including the leukemic blasts in acute myeloid leukemia can be induced to differentiate into CD1a-positive antigen-presenting dendritic cells in vitro. 13, 14 The new 'myeloid-based' model of hematopoiesis is one possible explanation for the unique features in our cases. This 'myeloid-based' model recognizes that myeloid potential persists even as lineage branches toward T and B cells 6, 7, [15] [16] [17] and proposes that T-and B-cell progenitors arise from common myelolymphoid progenitors through myeloid-T and myeloid-B stages. 18, 19 Previously published clonal relationship between LC histiocytosis and T-lymphoblastic leukemia and LC sarcoma and B-lymphoblastic leukemia further support that myeloid-T and myeloid-B precursors may be the cell of origin of these types of leukemia. 6, 7, [15] [16] [17] In 2008, Wada et al 20 provided evidence that there are progenitor cells in the adult thymus that have lost the potential to generate B cells but retain substantial macrophage potential as well as T-cell, natural killer cell and dendritic cell potential. 20 Our cases with evidence of myeloid and variable T-cell differentiation combined with a dendritic cell population (LC histiocytosis) suggests that they may have developed from this specific type of progenitor cell. The 'myeloid-based' model with myelolymphoid progenitors seems to improve on our understanding of unusual acute leukemias with mixed phenotypes as well as cases in which transdifferentiation was detected. Our cases further support this model as they show both mixed phenotypes and probable transdifferentiation.
